NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE
Clinical trials for NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE explained in plain language.
Never miss a new study
Get alerted when new NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE trials appear
Sign up with your email to follow new studies for NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to boost remission in tough lymphoma
Disease control TerminatedThis phase II trial tests whether adding either duvelisib or oral azacitidine to standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma that have not been treated yet. About 170 participants will receive one of three treatment combinat…
Matched conditions: NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo shows promise for rare blood cancer
Disease control OngoingThis early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…
Matched conditions: NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC